Exhibit 99.1

         Ibis Technology Announces Notice of Voluntary Dismissal Filed
               by Plaintiff in Shareholder Derivative Litigation

     DANVERS, Mass.--(BUSINESS WIRE)--April 10, 2007--Ibis Technology
Corporation (Nasdaq GM: IBIS - News), a leading provider of SIMOX-SOI
implantation equipment to the worldwide semiconductor industry, today announced
that the plaintiff in the shareholder derivative litigation pending in the
United States District Court for the District of Massachusetts against the
Company, as a nominal defendant, and certain of its directors and officers, has
filed a notice of voluntary dismissal with the Court. The notice of dismissal
provides that the shareholder derivative litigation will be dismissed with
prejudice and seeks the entry of an order by the Court confirming dismissal. The
notice also states that the plaintiff will receive a $55,000.00 payment upon the
Court's entry of an order of dismissal, in consideration of plaintiff's analysis
of information provided by the Company regarding, among other things, the
Company's contention that the litigation should be dismissed for failure to make
a demand on the Board of Directors before filing suit as required by
Massachusetts law. Such payment will be funded entirely by the Company's
insurance carrier.

     About Ibis Technology

     Ibis Technology Corporation is a leading provider of oxygen implanters for
the production of SIMOX-SOI (Separation-by-Implantation-of-Oxygen
Silicon-On-Insulator) wafers for the worldwide semiconductor industry.
Headquartered in Danvers, Massachusetts, the Company maintains an additional
office in Aptos, California. Ibis Technology is traded on the Nasdaq National
Market under the symbol IBIS. Information about Ibis Technology Corporation and
SIMOX-SOI is available on Ibis' web site at www.ibis.com.

     "Safe Harbor" Statement under the Private Securities Litigation Reform Act
of 1995

     This release contains express or implied forward-looking statements
regarding, among other things, (i) the Company's ability to conduct its
operations in a manner consistent with its current plan and existing capital
resources or otherwise to obtain additional implanter orders or to secure
financing to continue as a going concern, (ii) customer interest in and demand
for, and market acceptance of, the Company's SIMOX-SOI technology, (iii) the
Company's plan to focus on supplying implanters to wafer manufacturers, (iv) the
adequacy of the Company's cash resources for continuing and future operations,
and (v) the adoption rate of SOI technology, and (vi) the proposed resolution of
the litigation referenced above. Such statements are neither promises nor
guarantees, but rather are subject to risks and uncertainties which could cause
actual results to differ materially from those described in the forward-looking
statements. Such risks and uncertainties include, but are not limited to,
cessation as a going concern due to the depletion of the Company's cash reserves
at an unanticipated rate combined with an inability to obtain customer orders or
to secure financing, future continued migration to SOI technology and market
acceptance of SIMOX, the level of demand for the Company's products, the
Company's ability to pursue and maintain further strategic relationships,
partnerships and alliances with third parties, the Company's ability to protect
its proprietary technology, the potential trends in the semiconductor industry
generally, the ease with which an i2000 can be installed and qualified in
fabrication facilities, the likelihood that implanters, if ordered, will be
qualified and accepted by customers without substantial delay, modification, or
cancellation, in whole or in part, the likelihood and timing of revenue
recognition on such transactions, the impact of competitive products,
technologies and pricing, the impact of rapidly changing technology, the
possibility of further asset impairment and resulting charges, equipment
capacity and supply constraints or difficulties, the Company's limited history
in selling implanters, general economic conditions, and other risks and
uncertainties described in the Company's Securities and Exchange Commission
filings from time to time, including but not limited to, the Company's Annual
Report on Form 10-K for the year ended December 31, 2006. All information set
forth in this press release is as of April 10, 2007, and Ibis undertakes no duty
to update this information unless required by law.


    CONTACT: Ibis Technology Corporation
             William J. Schmidt, 978-777-4247
             Chief Financial Officer